[go: up one dir, main page]

WO2011063164A3 - Médicaments de cannabinoïde à libération prolongée - Google Patents

Médicaments de cannabinoïde à libération prolongée Download PDF

Info

Publication number
WO2011063164A3
WO2011063164A3 PCT/US2010/057302 US2010057302W WO2011063164A3 WO 2011063164 A3 WO2011063164 A3 WO 2011063164A3 US 2010057302 W US2010057302 W US 2010057302W WO 2011063164 A3 WO2011063164 A3 WO 2011063164A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
therapeutic
present
medicaments
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/057302
Other languages
English (en)
Other versions
WO2011063164A2 (fr
Inventor
David Carley
Peter Letendre
Kenton Fedde
John Koleng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEADY SLEEP RX CO Inc
Original Assignee
STEADY SLEEP RX CO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEADY SLEEP RX CO Inc filed Critical STEADY SLEEP RX CO Inc
Publication of WO2011063164A2 publication Critical patent/WO2011063164A2/fr
Publication of WO2011063164A3 publication Critical patent/WO2011063164A3/fr
Priority to US13/474,666 priority Critical patent/US20120231083A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un médicament qui conduit à l'administration d'un niveau thérapeutique d'un ou plusieurs cannabinoïdes pendant une fenêtre thérapeutique cliniquement appropriée. La fenêtre thérapeutique est une fenêtre plus longue que celle produite par un médicament à libération immédiate tel que Marinol contenant une quantité équivalente du cannabinoïde. L'administration orale des présentes compositions permet un dosage thérapeutique en maintenant des taux sûrs, sans effet secondaire, d'un cannabinoïde. La présente invention concerne en outre des procédés de traitement de troubles sensibles aux cannabinoïdes.
PCT/US2010/057302 2009-11-18 2010-11-18 Médicaments de cannabinoïde à libération prolongée Ceased WO2011063164A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/474,666 US20120231083A1 (en) 2010-11-18 2012-05-17 Sustained release cannabinoid medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26252309P 2009-11-18 2009-11-18
US61/262,523 2009-11-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/474,666 Continuation US20120231083A1 (en) 2010-11-18 2012-05-17 Sustained release cannabinoid medicaments

Publications (2)

Publication Number Publication Date
WO2011063164A2 WO2011063164A2 (fr) 2011-05-26
WO2011063164A3 true WO2011063164A3 (fr) 2011-10-06

Family

ID=44060346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/057302 Ceased WO2011063164A2 (fr) 2009-11-18 2010-11-18 Médicaments de cannabinoïde à libération prolongée

Country Status (1)

Country Link
WO (1) WO2011063164A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640379A4 (fr) * 2010-11-18 2014-08-13 Pier Pharmaceuticals Administration d'une faible dose de cannabinoïdes
WO2013009928A1 (fr) * 2011-07-11 2013-01-17 Organic Medical Research Formulations de cannabinoïdes
EP2739269A2 (fr) * 2011-08-01 2014-06-11 Ranbaxy Laboratories Limited Système d'administration de médicaments à libération contrôlée et dissolution améliorée pour médicaments peu solubles dans l'eau
EP2572731A1 (fr) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations à base de dispersions solides
US10350251B2 (en) * 2012-03-28 2019-07-16 Keith Gerald Freeman Medical compositions, methods of making and using those compositions, and kits including those compositions
CN103202811B (zh) * 2013-03-22 2015-04-15 中山大学 二氟尼柳固体分散体及其制备方法
WO2015025312A1 (fr) * 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions combinant une libération immédiate et une libération prolongée de cannabinoïdes, leurs méthodes de fabrication et d'utilisation
MX2016006657A (es) 2013-11-22 2016-10-12 CL BioSciences LLC Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
US11077086B2 (en) 2014-07-21 2021-08-03 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
EP3182970A4 (fr) * 2014-08-22 2018-03-21 Medipath Inc. Compositions et procédés d'enrobages en cannabinoïdes utilisés dans l'administration de médicaments
WO2016044370A1 (fr) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Composition cannabinoïde et méthode de traitement de la douleur
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA2974895A1 (fr) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Compositions et procedes de traitement de troubles epileptiques
CA2981285A1 (fr) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Compositions et methodes de traitement de troubles epileptiques
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CN105168163A (zh) * 2015-09-23 2015-12-23 中国药科大学 难溶性药物口服缓释干乳片及其制备方法
WO2017218629A1 (fr) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques
US11701323B2 (en) 2016-06-28 2023-07-18 Trichomeshell Ltd. Dosage form for vaporization and smoking
AU2018233582B2 (en) * 2017-03-16 2022-04-07 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
US11612581B2 (en) 2017-08-09 2023-03-28 Cannibite Bvba Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
WO2019074829A1 (fr) * 2017-10-09 2019-04-18 Rhodes Pharmaceuticals L.P. Compositions pharmaceutiques à base de résinate, et leurs procédés de fabrication et d'utilisation
AU2019213277B2 (en) * 2018-01-29 2024-11-14 Evero Compositions and methods for treating obstructive sleep apnea
CA3094267A1 (fr) * 2018-03-19 2019-09-26 Emerald Health Therapeutics Canada Inc. Capsule de cannabis a dose definie
AU2019306787B2 (en) * 2018-07-18 2025-05-29 Glatt Gmbh Extended release formulations of cannabinoids
US20210015743A1 (en) * 2019-07-16 2021-01-21 Yoseph Seyoum Treatment of irritable bowel and inflammatory bowel disease
WO2021151169A1 (fr) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Composition de cannabinoïdes et procédé de fabrication
WO2021151168A1 (fr) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Méthode de thérapie cannabinoïde
CA3198142A1 (fr) * 2021-01-29 2022-08-04 Edward M. Rudnic Compositions pharmaceutiques orales de cannabinoides et methodes de traitement de troubles du sommeil
US20230338399A1 (en) * 2022-04-22 2023-10-26 Curio Ip, Llc Oral cannabinoid pharmaceutical compositions and methods of treating inflammatory gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127572A1 (en) * 2001-04-06 2004-07-01 Carley David W. Functional role for cannabinoids in autonomic stability during sleep
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008070268A2 (fr) * 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Compositions pharmaceutiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127572A1 (en) * 2001-04-06 2004-07-01 Carley David W. Functional role for cannabinoids in autonomic stability during sleep
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008070268A2 (fr) * 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Compositions pharmaceutiques

Also Published As

Publication number Publication date
WO2011063164A2 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
WO2011063164A3 (fr) Médicaments de cannabinoïde à libération prolongée
WO2012068516A3 (fr) Administration d'une faible dose de cannabinoïdes
WO2012142511A3 (fr) Compositions orthomoléculaires et leur utilisation dans la stabilisation de la matrice extracellulaire
EP4570250A3 (fr) Combinaisons comprenant du brexpiprazole ou un sel de celui-ci et un second médicament pour une utilisation dans le traitement d'un trouble du snc
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
WO2011053792A3 (fr) Méthodes et compositions pour une libération prolongée de médicaments
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2006044421A3 (fr) Administration d'un medicament a action rapide, sans danger pour le systeme cardiovasculaire
WO2009102893A3 (fr) Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d<sb>2</sb>
MX369385B (es) Productos para cicatrizar heridas tisulares.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
WO2009065406A3 (fr) Nouveaux composés hydrocarbonés cycliques pour le traitement de maladies
WO2014022739A3 (fr) Agents constitués d'arni modifié
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
HK1198869A1 (en) Combination treatments for hepatitis c
DK2368547T3 (da) Antivirale sammensætninger, som omfatter geraniol og carvon
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2012125830A3 (fr) Association de la curcumine avec des antidiabétiques du diabète de type 2 utilisée pour prévenir et traiter les séquelles d'une maladie, les réactions indésirables associées à un traitement, et pour améliorer le contrôle de la glycémie
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
WO2010081091A3 (fr) Compositions thérapeutiques pour le traitement de troubles de la cornée
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10832214

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22-08-2012.)

122 Ep: pct application non-entry in european phase

Ref document number: 10832214

Country of ref document: EP

Kind code of ref document: A2